Oct 2016

probiodrug

Sole Global Coordinator & Joint Bookrunner

€ 14.9 million

Accelerated Bookbuild Offering

Probiodrug

Probiodrug is a biopharmaceutical company dedicated to the research and development of novel therapeutic solutions to treat people with Alzheimer’s Disease.

Accelerated bookbuild offering amounting to €14.9m.
Proceeds will be used to finance clinical development of their lead product and to support exploration and development of additional business opportunities.
Kempen & Co acted as Sole Global Coordinator and Joint Bookrunner in the transaction.